Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Buy" from Brokerages

Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) has received a consensus rating of "Buy" from the nine brokerages that are currently covering the stock, Marketbeat reports. Nine investment analysts have rated the stock with a buy rating. The average 1 year price objective among brokerages that have covered the stock in the last year is $7.00.

A number of research firms recently commented on TSHA. Jefferies Financial Group reiterated a "buy" rating and issued a $8.00 target price (up from $2.00) on shares of Taysha Gene Therapies in a research note on Tuesday. Needham & Company LLC reiterated a "buy" rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research note on Wednesday. Canaccord Genuity Group reiterated a "buy" rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, March 21st. Chardan Capital lifted their target price on shares of Taysha Gene Therapies from $5.00 to $7.00 and gave the stock a "buy" rating in a research note on Thursday, March 21st. Finally, JMP Securities restated a "market outperform" rating and set a $5.00 price objective on shares of Taysha Gene Therapies in a research note on Wednesday, March 20th.

Taysha Gene Therapies Stock Up 21.0 %

Shares of Taysha Gene Therapies stock traded up $0.54 on Wednesday, reaching $3.11. The stock had a trading volume of 4,684,978 shares, compared to its average volume of 2,449,883. The company has a 50 day moving average price of $2.62 and a 200 day moving average price of $2.11. The company has a quick ratio of 4.08, a current ratio of 4.08 and a debt-to-equity ratio of 0.54. Taysha Gene Therapies has a 1 year low of $0.50 and a 1 year high of $3.89. The stock has a market capitalization of $581.63 million, a P/E ratio of -4.64 and a beta of 0.37.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last released its earnings results on Tuesday, May 14th. The company reported ($0.10) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.01. The company had revenue of $3.41 million during the quarter, compared to analyst estimates of $3.70 million. During the same quarter last year, the business earned ($0.28) earnings per share. As a group, equities research analysts forecast that Taysha Gene Therapies will post -0.39 EPS for the current year.

Hedge Funds Weigh In On Taysha Gene Therapies

Several large investors have recently made changes to their positions in the company. Commonwealth Equity Services LLC lifted its stake in shares of Taysha Gene Therapies by 44.0% in the 3rd quarter. Commonwealth Equity Services LLC now owns 26,971 shares of the company's stock valued at $85,000 after purchasing an additional 8,246 shares during the period. Kovitz Investment Group Partners LLC increased its holdings in Taysha Gene Therapies by 66.7% in the 3rd quarter. Kovitz Investment Group Partners LLC now owns 25,000 shares of the company's stock worth $79,000 after acquiring an additional 10,000 shares in the last quarter. Howard Capital Management Inc. purchased a new stake in Taysha Gene Therapies in the 4th quarter worth $25,000. China Universal Asset Management Co. Ltd. increased its holdings in Taysha Gene Therapies by 66.1% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 35,908 shares of the company's stock worth $103,000 after acquiring an additional 14,286 shares in the last quarter. Finally, Victory Capital Management Inc. purchased a new stake in Taysha Gene Therapies in the 4th quarter worth $28,000. 77.70% of the stock is currently owned by institutional investors and hedge funds.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.